Literature DB >> 17573645

[Fuchs' heterochromic cyclitis without heterochromia: a diagnostic approach].

P Beneyto1, M J Fernández, A García, M Ibáñez, A García-Aparicio, P Morente.   

Abstract

OBJECTIVE: To obtain diagnostic guidelines of Fuchs' heterochromic cyclitis (FHC) in the absence of heterochromia using Bayesian methods.
METHODS: The pre-test and post-test likelihood that a certain patient without heterochromia (but with other characteristic symptoms of the disease such as iris nodules, cataracts, glaucoma or vitritis) has FCH, was assessed by the Bayes' theorem for conditioned likelihood. The prevalence values of FCH and the presentation rate of symptoms in FCH and in other forms of anterior uveitis were obtained from published literature data.
RESULTS: In the absence of heterochromia, the combination of iris nodules together with cataracts, vitritis or glaucoma, and the association of the last three symptoms in the absence of nodules, resulted in an accumulated likelihood of more than 50% of subjects having the disease.
CONCLUSIONS: The coincidence in one patient of several indicative symptoms, even in the absence of heterochromia, may make FCH a likely diagnostic option.

Entities:  

Mesh:

Year:  2007        PMID: 17573645     DOI: 10.4321/s0365-66912007000600007

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  3 in total

1.  Development and validation of a Bayesian network for the differential diagnosis of anterior uveitis.

Authors:  J J González-López; Á M García-Aparicio; D Sánchez-Ponce; N Muñoz-Sanz; N Fernandez-Ledo; P Beneyto; M C Westcott
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

Review 2.  [Fuchs uveitis].

Authors:  L Daas; B Seitz; U Pleyer
Journal:  Ophthalmologe       Date:  2017-05       Impact factor: 1.059

3.  High concordance of intraocular antibody synthesis against the rubella virus and Fuchs heterochromic uveitis syndrome in Slovenia.

Authors:  Spela Stunf; Miroslav Petrovec; Nina Žigon; Marko Hawlina; Aleksandra Kraut; Jolanda D F de Groot-Mijnes; Nataša Vidovič Valentinčič
Journal:  Mol Vis       Date:  2012-12-01       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.